Beneficial effects of growth hormone-releasing peptide on myocardial oxidative stress and left ventricular dysfunction in dilated cardiomyopathic hamsters

Circulation Journal

Volumn 74, Issue 1, 2010, Pages 163-170

  Kato, Yosuke ^a,b   Iwase, Mitsunori ^a,c   Ichihara, Sahoko ^d   Kanazawa, Hiroaki ^e   Hashimoto, Katsunori ^a   Noda, Akiko ^a   Nagata, Kohzo ^a   Koike, Yasuo ^a   Yokota, Mitsuhiro ^f  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOYOTA MEMORIAL HOSPITAL   (Japan)

^d MIE UNIVERSITY   (Japan)

^e UNIVERSITY OF SHIZUOKA   (Japan)

^f AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Dilated cardiomyopathy; Growth hormone releasing peptide; Hamsters; Heart failure; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; GLUTATHIONE; GLUTATHIONE DISULFIDE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; PRALMORELIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG INHIBITION; DRUG MEGADOSE; HAMSTER; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HYPOTHESIS; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; SYSTOLIC DYSFUNCTION;

ALDEHYDES; ANIMALS; CARDIOMYOPATHY, DILATED; CRICETINAE; DISEASE MODELS, ANIMAL; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; MALE; MESOCRICETUS; MUTATION; MYOCARDIUM; OLIGOPEPTIDES; OXIDATIVE STRESS; SARCOGLYCANS; SUPEROXIDE DISMUTASE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 75149141377     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0378     Document Type: Article

References (39)

1. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The causes of dilated cardiomyopathy: A clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23: 586-590.
2. Singal PK, Khaper N, Palace V, Kumar D. The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 1998; 40: 426-432.
3. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999; 85: 357-363.
4. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-2092.
5. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-814.
6. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hänlein D, Willenbrock R, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-1237.
7. Bodart V, Bouchard JF, McNicoll N, Escher E, Carrière P, Ghigo E, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 1999; 85: 796-802.
8. Iwase M, Kanazawa H, Kato Y, Nishizawa T, Somura F, Ishiki R, et al. Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters. Cardiovasc Res 2004; 61: 30-38.
9. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997; 94: 13873-13878.
10. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106: 655-662.
11. Kato Y, Iwase M, Takagi K, Nishizawa T, Kanazawa H, Matsushita A, et al. Differential myolysis of myocardium and skeletal muscle in hamsters with dilated cardiomyopathy: Beneficial protective effect of diltiazem. Circ J 2006; 70: 1497-1502.
12. Nishizawa T, Iwase M, Kanazawa H, Ichihara S, Ichihara G, Nagata K, et al. Serial alterations of β-adrenergic signaling in dilated cardiomyopathic hamsters: Possible role of myocardial oxidative stress. Circ J 2004; 68: 1051-1060.
13. Ichihara S, Yamada Y, Ichihara G, Kanazawa H, Hashimoto K, Kato Y, et al. Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun 2006; 350: 105-113.
14. Hayashi K, Kimata H, Obata K, Matsushita A, Fukata A, Hashimoto K, et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. J Card Fail 2008; 14: 238-244.
15. Kato Y, Iwase M, Kanazawa H, Nishizawa T, Zhao YL, Takagi K, et al. Validity and application of noninvasive measurement of blood pressure in hamsters. Exp Anim 2003; 52: 359-363.
16. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-522.
17. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980; 106: 207-212.
18. Spies-Martin D, Sommerburg O, Langhans CD, Leichsenring M. Measurement of 4-hydroxynonenal in small volume blood plasma samples: Modification of a gas chromatographic-mass spectrometric method for clinical settings. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 774: 231-239.
19. Crapo JD, McCord JM, Fridovich I. Preparation and assay of superoxide dismutases. Methods Enzymol 1978; 53: 382-393.
20. Whanger PD, Butler JA. Effects of various dietary levels of selenium as selenite or selenomethionine on tissue selenium levels and glutathione peroxidase activity in rats. J Nutr 1988; 118: 846-852.
21. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, et al. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung 2004; 54: 868-880.
22. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388.
23. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 2008; 72(Suppl A): A-31-A-37.
24. Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K, Suzuki S, et al. Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 2007; 71: 1040-1046.
25. Masano T, Kawashima S, Toh R, Satomi-Kobayashi S, Shinohara M, Takaya T, et al. Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: The possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase. Circ J 2008; 72: 1512-1519.
26. Nishikimi T, Karasawa T, Inaba C, Ishimura K, Tadokoro K, Koshikawa S, et al. Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: A pilot study. Circ J 2009; 73: 892-898.
27. Blasig IE, Grune T, Schönheit K, Rohde E, Jakstadt M, Haseloff RF, et al. 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol 1995; 269: H14-H22.
28. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-2871.
29. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11: 376-381.
30. Berlanga J, Cibrian D, Guevara L, Dominguez H, Alba JS, Seralena A, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond) 2007; 112: 241-250.
31. Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R, et al. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens 2006; 19: 764-767.
32. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation 2004; 109: 2221-2226.
33. Filigheddu N, Fubini A, Baldanzi G, Cutrupi S, Ghè C, Catapano F, et al. Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death. Endocrine 2001; 14: 113-119.
34. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-1037.
35. Weekers F, Van Herck E, Isgaard J, Van den Berghe G. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology 2000; 141: 3993-3999.
36. Xu XB, Pang JJ, Cao JM, Ni C, Xu RK, Peng XZ, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol 2005; 289: H1643-H1651.
37. Furuta S, Hori T, Ohyama T. KP-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 360-366.
38. Haenen GR, Plug HJ, Vermeulen NP, Timmerman H, Bast A. Contribution of 4-hydroxy-2,3-trans-nonenal to the reduction of beta-adrenoceptor function in the heart by oxidative stress. Life Sci 1989; 45: 71-76.
39. Ebina T, Toya Y, Oka N, Schwencke C, Kawabe J, Ishikawa Y. Isoform-specific regulation of adenylyl cyclase by oxidized catecholamines. J Mol Cell Cardiol 1997; 29: 1247-1254.